Urogen Pharma (NASDAQ:URGN) Receives Consensus Rating of "Buy" from Analysts

Key Points

• Urogen Pharma has received a consensus rating of "Buy" from nine analysts, with one holding a strong buy rating and seven assigning buy ratings, while the average twelve-month price target is $32.00.
• Insider transactions showed significant sales; Mark Schoenberg sold 10,000 shares at an average price of $17.69, reducing his stake by 6.32%.
• Urogen Pharma's stock performance reveals a one-year low of $3.42 and a high of $21.01, while the company posted a quarterly EPS of ($1.05), missing estimates.

Urogen Pharma (NASDAQ:URGN - Get Free Report) has received a consensus rating of "Buy" from the nine analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $32.00.

Several equities research analysts have recently commented on the company. Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. Piper Sandler assumed coverage on Urogen Pharma in a report on Monday, August 18th. They set an "overweight" rating and a $36.00 target price for the company. Guggenheim reaffirmed a "buy" rating and set a $30.00 target price (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. The Goldman Sachs Group set a $16.00 target price on Urogen Pharma and gave the company a "neutral" rating in a report on Friday, June 13th. Finally, Oppenheimer set a $31.00 target price on Urogen Pharma and gave the company a "buy" rating in a report on Friday, June 13th.

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the firm's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the completion of the sale, the insider directly owned 148,229 shares in the company, valued at approximately $2,622,171.01. This trade represents a 6.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,522 shares of the firm's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $143,971.08. Following the sale, the general counsel owned 41,492 shares of the company's stock, valued at $794,156.88. The trade was a 15.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,833 shares of company stock valued at $457,467 over the last 90 days. Corporate insiders own 4.70% of the company's stock.

Institutional Investors Weigh In On Urogen Pharma

Institutional investors have recently bought and sold shares of the business. Osaic Holdings Inc. boosted its position in Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company's stock worth $50,000 after acquiring an additional 3,070 shares during the period. CWM LLC grew its stake in Urogen Pharma by 6,047.1% in the first quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after purchasing an additional 5,140 shares in the last quarter. Lazard Asset Management LLC purchased a new position in Urogen Pharma in the fourth quarter valued at about $67,000. Tower Research Capital LLC TRC grew its stake in Urogen Pharma by 422.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company's stock valued at $94,000 after purchasing an additional 5,571 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Urogen Pharma by 6,908.4% in the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after purchasing an additional 7,392 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Stock Performance

URGN opened at $18.88 on Friday. Urogen Pharma has a one year low of $3.42 and a one year high of $21.01. The stock's fifty day moving average is $17.54 and its 200-day moving average is $12.53. The company has a market capitalization of $873.39 million, a PE ratio of -5.69 and a beta of 1.10.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%.The firm had revenue of $24.22 million during the quarter, compared to the consensus estimate of $23.06 million. On average, equities research analysts forecast that Urogen Pharma will post -3.12 EPS for the current fiscal year.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.